December 17, 2003
Genta Appoints Pharmaceutical Industry Veteran, Peter T. Tattle, to its Board of Directors
December 9, 2003
Genta Completes New Drug Application for Approval of Genasense<sup>TM</sup> in Patients with Advanced Malignant Melanoma
December 9, 2003
Genasense<sup>TM</sup> Reported Active in Combination with Chemotherapy in Multiple Myeloma
December 8, 2003
<span>Genasense<sup>TM</sup> plus Rituxan® Reported Active in Non-Hodgkin's Lymphoma<br /></span>
December 8, 2003
<span>Genasense<sup>TM</sup> plus Chemotherapy Reported Active as Initial Treatment for Older Patients with Acute Myeloid Leukemia</span>
November 24, 2003
Genasense<sup>TM</sup> Featured in Presentations at the Annual Meeting of the American Society of Hematology
November 19, 2003
Preclinical Studies Demonstrate Activity of Genasense<sup>TM</sup> Alone and in Combination with Radiation Therapy
November 14, 2003
Phase 3 Trial Results of Genasense<sup>TM</sup> Plus Chemotherapy in Patients with Advanced Malignant Melanoma Reported at Scientific Meeting
October 30, 2003
Genta Reports Achievement of Major Corporate Milestones in Third Quarter 2003
October 28, 2003
Genta Incorporated Announces Conference Call and Webcast to Discuss Third Quarter 2003 Earnings
October 17, 2003
Genta Incorporated to Present at Rodman & Renshaw Techvest HealthcareConference
September 18, 2003
Genta to Present at UBS Global Life Sciences Conference
September 18, 2003
FDA Approves Genta's First Product, Ganite<sup>TM</sup>, for the Treatment of Cancer - Related Hypercalcemia
September 10, 2003
Genta and Aventis Report Positive Results in Phase 3 Trial of GenasenseTM Plus Chemotherapy in Patients with Advanced Malignant Melanoma
September 9, 2003
Genta and Aventis Announce Conference Call and Webcast to Discuss Phase 3 Clinical Results of Genasense<sup>TM</sup>
September 9, 2003
Genta to Hold Investor and Analyst Meeting Tomorrow to Discuss Phase 3 Clinical Results of Genasense<sup>TM</sup>
August 22, 2003
Genta Acquisition of Salus Therapeutics, Inc. Completed
August 14, 2003
Genta to Acquire Salus Therapeutics, Inc., Expanding Leadership Position in DNA/RNA-Based Medicines
July 31, 2003
Genta Announces 2nd Quarter 2003 Financial Results and Highlights
July 30, 2003
Genta Initiates New Genasense<sup>TM</sup> Trial in Patients with Chronic Lymphocytic Leukemia
July 24, 2003
Genta Announces Conference Call and Webcast to Discuss Second Quarter 2003 Earnings
June 30, 2003
Genta Receives FDA Fast Track Designation for Genasense<sup>TM</sup> in Chronic Lymphocytic Leukemia
June 26, 2003
Genta Broadens Genasense<sup>TM</sup> Anticancer Clinical Trials
June 13, 2003
Genta Incorporated Announces Webcast of 2003 Annual Shareholders Meeting
June 11, 2003
Genta Announces New Clinical Trial of Genasense<sup>TM</sup> in Patients with Advanced Breast Cancer
June 4, 2003
Genta To Present At Needham & Company Second Annual Biotechnology Conference
June 4, 2003
Preclinical Results Show Genasense<sup>TM</sup> Synergizes with Campath® in Chronic Lymphocytic Leukemia
June 3, 2003
Genasense<sup>TM</sup> Plus Taxotere® Reported Active in Patients with Hormone-Refractory Prostate Cancer at ASCO Meeting
June 3, 2003
Genasense<sup>TM</sup> Combination with Chemotherapy Reported Useful in Newly Diagnosed Patients with Small Cell Lung Cancer
June 2, 2003
Clinical Study Results Show Genasense<sup>TM</sup> May Delay Progression in Patients with Aggressive Non-Hodgkin's Lymphoma
May 27, 2003
Genta Announces Promotion of Dr. Loretta M. Itri to President, Pharmaceutical Development
May 27, 2003
Clinical Activity of Genasense in Patients with Refractory Myeloma Highlighted in Multiple Presentations at International Scientific Meeting
May 1, 2003
Genta Announces 1st Quarter 2003 Financial Results and Highlights
April 25, 2003
Genta Incorporated Announces Conference Call and Webcast to Discuss First Quarter 2003 Earnings
April 10, 2003
New Study Shows Biomarkers May Determine Responsiveness to Ganite<sup>TM</sup> in Non-Hodgkin's Lymphoma
April 9, 2003
Single-Agent Activity of Genta's Lead Anticancer Compound, Genasense<sup>TM</sup>, Reported in Nasopharyngeal Carcinoma
April 8, 2003
Preclinical Activity of Genasense<sup>TM</sup> Documented in Non-Small Cell Lung Cancer both Alone and in Combination with Navelbine® Chemotherapy
April 7, 2003
New Preclinical Data Demonstrate Optimized Treatment Schedules of Genasense<sup>TM</sup> and Taxotere® in Prostate Cancer
April 1, 2003
Genta Completes FDA Submission of New Drug Application for Ganite<sup>TM</sup> (gallium nitrate injection)
March 26, 2003
Genta CEO Provides Clinical, Regulatory, and Financial Update at Banc of America Conference
March 19, 2003
Genta Incorporated To Present At Banc of America 2003 Healthcare Conference
March 17, 2003
Genta Establishes $40 Million Line of Credit with Aventis for Genasense<sup>TM</sup> Collaborative Program
February 25, 2003
Genta Incorporated to Present at Raymond James Annual Institutional Investors Conference
February 21, 2003
Genta Incorporated to Present in Roundtable and Corporate Sessions at BIO CEO & Investor Conference
February 13, 2003
Genta Reports Fourth Quarter and Year End 2002 Results and Progress
January 23, 2003
Genta Incorporated To Present at U.S. Bancorp Piper Jaffray Health Care Conference
January 7, 2003
Genta Provides Clinical and Regulatory Update on its Lead Anticancer Compound, Genasense<sup>TM</sup> , at JP Morgan H&Q Conference
January 3, 2003
Genta Announces Reactivation of New Drug Application (NDA) for Ganite<sup>TM</sup> and Initiation of CMC Regulatory Filings Submissions Intended to Enable Product Launch during 2003
